Free Trial

Weiss Ratings Reiterates Hold (C+) Rating for Smith & Nephew SNATS (NYSE:SNN)

Smith & Nephew SNATS logo with Medical background

Key Points

  • Weiss Ratings has reaffirmed a "hold (C+)" rating for Smith & Nephew SNATS (NYSE:SNN) as of Wednesday, indicating a cautious outlook on the stock.
  • The average price target for Smith & Nephew SNATS is $36.00, with several analysts rating it a "hold" and one analyst downgrading it from "strong-buy" to "buy".
  • Smith & Nephew SNATS shares saw a 0.6% increase, trading at $35.93, with significant institutional investment as 25.64% of stocks are held by hedge funds and other institutional investors.
  • Five stocks we like better than Smith & Nephew SNATS.

Smith & Nephew SNATS (NYSE:SNN - Get Free Report)'s stock had its "hold (c+)" rating restated by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday, October 3rd. Canaccord Genuity Group lifted their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, August 18th. Seven investment analysts have rated the stock with a Hold rating, According to MarketBeat, Smith & Nephew SNATS has an average rating of "Hold" and an average target price of $36.00.

Get Our Latest Research Report on SNN

Smith & Nephew SNATS Stock Up 0.6%

Shares of SNN stock traded up $0.20 during trading hours on Wednesday, reaching $35.93. 427,108 shares of the company's stock were exchanged, compared to its average volume of 666,709. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The stock's 50 day moving average is $36.44 and its 200-day moving average is $31.35. Smith & Nephew SNATS has a fifty-two week low of $23.69 and a fifty-two week high of $38.79. The company has a market cap of $15.65 billion, a price-to-earnings ratio of 16.63, a P/E/G ratio of 0.98 and a beta of 0.69.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently made changes to their positions in SNN. Hexagon Capital Partners LLC grew its holdings in Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after purchasing an additional 406 shares during the period. Richards Merrill & Peterson Inc. grew its holdings in Smith & Nephew SNATS by 500.0% during the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 1,000 shares during the last quarter. AlphaCore Capital LLC acquired a new position in Smith & Nephew SNATS in the second quarter valued at $44,000. Bessemer Group Inc. lifted its holdings in Smith & Nephew SNATS by 3,471.4% in the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new stake in shares of Smith & Nephew SNATS during the 1st quarter worth approximately $52,000. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

(Get Free Report)

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Recommended Stories

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Smith & Nephew SNATS Right Now?

Before you consider Smith & Nephew SNATS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.

While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.